Xia co‑founded Akeso in 2012 and has served as chairwoman, president and CEO since inception. Since 2023, she has served on the board of Summit Therapeutics. Under Xia, Akeso have developed
Ivonescimab, which appears to outperform
Pembrolizumab (marketed as Keytruda), produced by
Merck in the US. In March 2025, she was included in the "TIME100 Health" list. As of July 2025,
Forbes estimates her net worth at US$1.2 billion. ==References==